Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nick R. Anderson"'
Autor:
Janusz H. Hankiewicz, Noweir Alghamdi, Nicholas M. Hammelev, Nick R. Anderson, Robert E. Camley, Karl Stupic, Marek Przybylski, Jan Zukrowski, Zbigniew J. Celinski
Publikováno v:
AIP Advances, Vol 7, Iss 5, Pp 056703-056703-6 (2017)
We investigate the use of Cu0.35Zn0.65Fe2O4 particles as temperature-dependent sensors in magnetic resonance imaging (MRI). This material has a Curie temperature near 290 K, but in the large magnetic fields found in MRI scanners, there is a significa
Externí odkaz:
https://doaj.org/article/ad401963c94c46c587b0eb852577d137
Autor:
Harish Kumar, Andrew J. Paterson, Nick R Anderson, Shaowei Qiu, Sabyasachi Sanyal, Ravi Bhatia
Publikováno v:
Blood. 140:11533-11534
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e2a16476b6eb0674b475bf2d01ab0ff
https://doi.org/10.1182/blood-2022-169220
https://doi.org/10.1182/blood-2022-169220
Autor:
Harish Kumar, Aditi Dhir, Andrew J. Paterson, Nick R Anderson, Shaowei Qiu, Xinyang Zhao, Rui Lu, Ravi Bhatia
Publikováno v:
Blood. 140:3073-3074
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76f7ca23e7d60dc8025d269f665a5b46
https://doi.org/10.1182/blood-2022-168326
https://doi.org/10.1182/blood-2022-168326
Autor:
Mason W Harris, Nick R Anderson, Amanda K Mullen, Ravi Bhatia, Andrew J. Paterson, Shaowei Qiu, Hui Li
Publikováno v:
Blood. 136:7-8
One of the most common mutations in adult AML is a constitutively activating internal tandem duplication in the juxtamembrane domain of the Flt3 receptor (Flt3-ITD), which portends poor prognosis due to high recurrence rates and defines a distinct su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89a7b312ba6e0f203631b9a5f565c239
https://doi.org/10.1182/blood-2020-142579
https://doi.org/10.1182/blood-2020-142579
Autor:
Lita M. Araysi, Joel L. Berry, Hawley C. Pruitt, Andra R. Frost, Nick R Anderson, Susan M. Lobo-Ruppert, Rajeev S. Samant, Kayla F. Goliwas, Jillian R. Richter
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
The use of in vitro, engineered surrogates in the field of cancer research is of interest for studies involving mechanisms of growth and metastasis, and response to therapeutic intervention. While biomimetic surrogates better model human disease, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258a1b39c912f9ac3f405099e02bb1d1
https://doi.org/10.1038/s41598-017-14326-8
https://doi.org/10.1038/s41598-017-14326-8
Publikováno v:
Blood. 134:909-909
The Flt3-ITD is one of the most common mutations in AML, and defines a distinct subtype of disease with unique features and biology, and with poor prognosis related to high rates of recurrence. Although several FLT3 TKIs have been developed for clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d67d018b79ac58969eaf132ea999bff
https://doi.org/10.1182/blood-2019-124379
https://doi.org/10.1182/blood-2019-124379
Publikováno v:
Blood. 134:2524-2524
FLT3-ITD mutations are seen in 20-30% of adult and 15% of pediatric acute myeloid leukemia (AML) patients and are associated with poor prognosis with higher rates of relapse and therapy resistance. FLT3 tyrosine kinase inhibitors (TKIs) have shown so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c482dd27fa3f7a68b14f59e505ccdc62
https://doi.org/10.1182/blood-2019-125178
https://doi.org/10.1182/blood-2019-125178
Autor:
Puneet Agarwal, Min Xie, Jianbo He, Andrew J. Paterson, Ravi Bhatia, Nick R Anderson, Hui Li, Chengcheng Yan, Shaowei Qiu, Robert S. Welner, Rui Lu, Jing Yang, Mansi Shah, Ajay Abraham
Publikováno v:
Blood. 134:2548-2548
The FLT3-ITD mutation occurs in 25-30% of AML patients, and is associated with increased relapse rate and poor survival. FLT3 tyrosine kinase inhibitors (TKI) have shown encouraging results, but responses are not sustained. Therefore, there is consid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09b2f5f285ff32ea6e848a2782e32201
https://doi.org/10.1182/blood-2019-124948
https://doi.org/10.1182/blood-2019-124948
Autor:
Mason W Harris, Amanda K Mullen, Puneet Agarwal, Ravi Bhatia, Nick R Anderson, Shaowei Qiu, Hui Li, Ajay Abraham, Andrew J. Paterson, Jianbo He, Mansi Shah
Publikováno v:
Blood. 132:1358-1358
The FLT3-ITD mutation occurs in 25-30% of AML patients, and is associated with increased relapse rate and poor survival. FLT3 tyrosine kinase inhibitors (TKI) have shown encouraging results, but responses are not sustained in most patients. Therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe4b6e47d6722aa7d06cd3ba517dc058
https://doi.org/10.1182/blood-2018-99-115702
https://doi.org/10.1182/blood-2018-99-115702